Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus

References

• Lockshin M. Does lupus flare during pregnancy?. Lupus 1993; 2: 1–2
   PubMed Web of Science ®Google Scholar
• Jungers P, Dougados M, Pelissier C, Kuttenn F, Tron F, Lesavre P, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 618–623
   PubMed Web of Science ®Google Scholar
• Lucas JA, Ahmed SA, Casey ML, MacDonald PC. Prevention of autoantibody formation and prolonged survival in New Zealand black/New Zealand white F1 mice fed dehydroisoandrosterone. J Clin Investig 1985; 75: 2091–2093
   PubMed Web of Science ®Google Scholar
• Lahita RG, Bradlow HL, Ginzler E, Pang S, New M. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 241–248
   PubMed Web of Science ®Google Scholar
• Parker L. Control of adrenal androgen secretion. Endocrin Metab Clin N Am 1991; 20: 401–421
   PubMed Web of Science ®Google Scholar
• Gebre-Medhin G, Husebye ES, Mallmin H, Helstrom L, Berne C, Karlsson FA, et al. Oral dehydroepiandrosterone (DHEA) replacement therapy in women with Addison's disease. Clin Endocrinol 2000; 52: 775–780
   PubMed Web of Science ®Google Scholar
• Johannsson G, Burman P, Wiren L, Engstrom BE, Nilsson AG, Ottosson M, et al. Low dose dehydroepiandrosterone affects behaviour in hypopituitary androgen-deficient women: A placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 2046–2052
   PubMed Web of Science ®Google Scholar
• Arlt W, Callies F, Vlijmen JCv, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Eng J Med 1999; 341: 1013–1020
   PubMed Web of Science ®Google Scholar
• Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, et al. Replacement of dehydroepiandrosterone in adrenal failure: No benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003; 88: 1112–1118
   PubMed Web of Science ®Google Scholar
• Vollenhoven RFv, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995; 38: 1826–1831
   PubMedGoogle Scholar
• Vollenhoven RFv, Morabito LM, Engleman EG, McGuire JL. Treatment of systemic lupus erythematosus with dehydroepiandrosterone. 50 patients treated up to 12 months. J Rheumatol 1998; 25: 285–289
   PubMedGoogle Scholar
• Vollenhoven RFv, Park JL, Genovese MC, West JP, McGuire JL. A double-blind, placebocontrolled, clinical trial of dehydroepiandrosterone in severe lupus erythematosus. Lupus 1999; 8: 181–187
   PubMedGoogle Scholar
• Petri MA, Lahita RG, Vollenhoven RFv, Merrill JT, Schiff M, Ginzler EM, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus. Arthritis Rheum 2002; 46: 1820–1829
   PubMed Web of Science ®Google Scholar
• Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004; 50: 2858–2868
   PubMed Web of Science ®Google Scholar
• Chang D-M, Lan J-L, Lin H-Y, Luo S-F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2924–2927
   PubMed Web of Science ®Google Scholar
• Gilboe I-M, Kvien TK, Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. Rheumatology 1999; 26: 1694–1700
   Google Scholar
• Rinaldi S, Doria A, Salaffi F, Ermani M, Iaccarino L, Ghirardello A, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology 2004; 43: 1574–1579
   PubMed Web of Science ®Google Scholar
• Doria A, Rinaldi S, Ermani M, Salaffi F, Iaccarino L, Ghirardello A, et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and physiological determinants. Rheumatology 2004; 43: 1580–1586
   PubMed Web of Science ®Google Scholar
• Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2682–2688
   PubMed Web of Science ®Google Scholar
• Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369
   PubMed Web of Science ®Google Scholar
• Nordenskjold UM, Grimby G. Grip force in patients with rheumatoid arthritis and fibromyalgia and in healthy subjects. A study with Grippit instrument. Scand J Rheumatol 1993; 22: 14–19
   PubMedGoogle Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–1447
   PubMed Web of Science ®Google Scholar
• Ware JE, Sherbourne CD. The MOS36-item short-form health survey (SF-36). Med Care 1992; 30: 473–483
   PubMed Web of Science ®Google Scholar
• Sullivan M, Karlsson J, Ware J. SF-36. Swedish manual and interpretation guide. Sahlgrenska University Hospital, Gothenburg 1994
   Google Scholar
• Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health summary scales: A users manual. The Health Institute, New England Medical Centre, Boston 1994
   Google Scholar
• Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins symptom checklist (HSCL): A self-report symptom inventory. Behav Sci 1974; 19: 1–15
   PubMedGoogle Scholar
• Joborn C, Hetta J, Lind L, Rastad J, Akerström G, Ljunghall S. Self-rated psychiatric symptoms in patients operated on because of primary hyperparathyroidism and in patients with long-standing mild hypercalcemia. Surgery 1989; 105: 72–78
   PubMed Web of Science ®Google Scholar
• Dupuy H. The Psychological General Well-Being scale (PGWB) Index. Assessment of quality of life in clinical trials of cardiovascular therapies, N Wenger, M Mattson, C Furberg, J Elinson. Le Jacq Publishing Inc., New York 1984; 170–183
   Google Scholar
• Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8–13
   PubMedGoogle Scholar
• McCoy NL, Davidson JM. A longitudinal study of the effects of menopause on sexuality. Maturitas 1985; 7: 203–210
   PubMed Web of Science ®Google Scholar
• Wiklund I, Karlberg J, Mattsson L-A. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: A double-blind placebo-controlled study. Am J Obstet Gynecol 1993; 168: 824–830
   PubMed Web of Science ®Google Scholar
• Burman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, et al. Quality of life in adults with growth hormone (GH) deficiency: Response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995; 80: 3585–3590
   PubMed Web of Science ®Google Scholar
• Strand V, Aranow C, Cardiel MH, Alarcon-Segovia D, Furie R, Sherrer Y, et al. Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo. Lupus 2003; 12: 677–686
   PubMed Web of Science ®Google Scholar
• Strand V. Clinical trial design in systemic lupus erythematosus: Lessons learned and future directions. Lupus 2004; 13: 406–411
   PubMed Web of Science ®Google Scholar
• Strand M, Hetta J, Rosen A, Sorensen S, Malmstrom R, Fabian C, et al. A double-blind, controlled trial in primary care patients with generalized anxiety: A comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51: 40–45
   PubMedGoogle Scholar
• Morales AJ, Nolan JJ, Nelson JC, Yen SSC. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994; 78: 1360–1367
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Roberts E. Dehydroepiandrosterone treatment of depression. Biol Psychiatry 1997; 41: 311–318
   PubMed Web of Science ®Google Scholar
• Melchior CL, Rizmann RF. Dehydroepiandrosterone is an anxiolytic in mice on the plus maze. Pharmacol Biochem Behav 1994; 47: 437–441
   PubMed Web of Science ®Google Scholar
• Abadie JM, Wright B, Correa G, Browne ES, Porter JR, Svec F. Effect of dehydroepiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat: The Obesity Research Program. Diabetes 1993; 42: 662–669
   PubMed Web of Science ®Google Scholar
• Straub RH, Konecna L, Hrach S, Rothe G, Kreutz M, Scholmerich J. Serum dehydroepiendrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: Possible link between endocrinosenescence and immunosenescence. J Clin Endocrinol Metab 1998; 83: 2012–2017
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: A putative role in pathogenesis. J Immunol 1991; 147: 117–123
   PubMed Web of Science ®Google Scholar
• Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000; 9: 498–503
   PubMed Web of Science ®Google Scholar
• Balschun D, Wetzel W, Rey AD, Pitossi F, Schneider H, Zuscratter W, et al. Interleukin-6: A cytokine to forget. FASEB J 2004; 18: 1788–1790
   PubMedGoogle Scholar